GlobeNewswire by notified

Aktana Launches Contextual Intelligence 360 to Solve the Challenge of Personalizing Customer Engagement at Scale

Share

New Solution Serves as the Intelligence Command Center for Life Sciences Commercial and Medical Teams

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aktana, the leader in intelligent customer engagement for the global life sciences industry, today announced Contextual Intelligence 360, a new, modular solution that enables commercial teams to rapidly scale AI-driven programs that personalize the customer experience, coordinate engagement and optimize the entire customer journey across channels.

Contextual Intelligence 360 builds on Aktana’s legacy AI strength in sales channel optimization to bring the same level of machine learning precision and contextual insights to all commercial activities. The solution can be configured to each brand’s unique strategy, incorporates any data or AI model, and can quickly extend across teams, franchises and regions. As part of the Contextual Intelligence 360 vision, commercial and medical teams will be able to expertly coordinate all of their interactions across the entire workflow from a single user interface.

Life sciences companies have been struggling to fit the pieces of the omnichannel puzzle together for more than a decade, even with continued advancement in AI and machine learning technologies. Data quality, vendor complexity, and change management challenges have challenged global rollouts. Now, as the use of digital is skyrocketing and HCPs are time-constrained like never before, coordinated omnichannel engagement with HCPs is crucial for success.

“One of our goals is to create meaningful and relevant interactions with physicians to support them in prioritizing patient care and taking into consideration their preferences,” said Quentin Lepont, global head of customer excellence & operations at Biogen. “We are upgrading our digital infrastructure with scalable artificial intelligence solutions and we are pleased to collaborate with Aktana on innovative programs to enable our teams to deliver personalized, coordinated experiences for our customers globally.”

Aktana’s Contextual Intelligence 360 includes the following components:

  • HCP Engagement AI – Pre-built machine learning modules dynamically identify individual customer preferences across content, channel, and timing. Rich context and clear explanations accompany every next-best-action recommendation to build user trust and drive adoption.

  • Commercial Team Empowerment Suite – Products and capabilities that provide AI-driven guidance and deep insights to brand leads, analytics teams, marketers, district managers, sales reps, hybrid reps and medical teams. With shared visibility into each HCP’s interaction history plus integrated workflow tools, companies can leverage the power of a coordinated team to deliver a better customer experience.

  • Customer Journey Management – An intuitive journey creation tool and the industry’s largest library of pre-defined customer journeys and commercial workflows enable commercial teams to quickly plan and deploy dynamic programs that meet both short- and long-term strategic goals.

  • Contextual Intelligence Engine 2.0 – An AI-driven optimization engine that finds the best combination of all possible actions, in all channels, and by all team members to create compelling omnichannel experiences for each physician. With transparency on the logic behind suggestions, users understand the necessary trade-offs to reconcile business strategy with organizational constraints.

  • Open Platform – A highly configurable platform that connects the commercial tech stack and integrates with any data source, analytics model and third-party system to allow companies to embed intelligence across a unified omnichannel ecosystem. Organizations can start small or launch in multiple countries at once using a common regional instance.

“The life sciences industry is at a critical inflection point: Coordinate personal engagement with HCPs, or lose their trust,” said Derek Choy, president at Aktana. “Our latest innovations, such as AI-driven optimization, allow companies of all sizes to achieve their omnichannel goals and form long-term relationships with physicians, ushering in a whole new generation of software that applies AI in a way that is contextual, flexible and transparent.”

Contextual Intelligence 360 will be available globally in November 2021. Learn more at Aktana’s upcoming webinar on November 10th, 2021. Details to follow on aktana.com.

In other news today, Aktana announced the launch of its next-generation Contextual Intelligence Engine.

About Aktana
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from nearly 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.

Media Contact:
Lisa Barbadora
610-420-3413
lbarbadora@barbadoraink.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

Robex Announces Share Consolidation29.3.2024 00:30:00 CET | Press release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, March 28, 2024 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX) announces today that its Board of Directors has approved the implementation of the consolidation of the issued and outstanding common shares of the Company approved by its shareholders on June 29, 2023, on the basis of one (1) post-consolidation common share for ten (10) pre-consolidation common shares (the "Consolidation"), which will take effect on April 1st, 2024 (the "Effective Date"). As a result, the Company's consolidated shares are expected to commence trading on the TSX Venture Exchange a few days after the Effective Date. After the Consolidation, the shares will have a new CUSIP number and a new ISIN number. The Consolidation will reduce the number of issued and outstanding common shares of the Company from approximately 844,054,403 common shares to 84,405,449 common shares upon complet

HiddenA line styled icon from Orion Icon Library.Eye